This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented ...

Earlier this year, we talked about why Arvinas stock (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, is vulnerable to downside risk.

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements.

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, has fallen 24% in a month, while it’s down a ...

Arvinas on Wednesday said Houston, who has been president and chief executive of the New Haven, Conn., company since September 2017, will retire from those positions upon the appointment of a ...

Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company that is pioneering a novel approach to treating serious diseases.Unlike conventional drugs, which inhibit the activity of disease ...

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with ...